Vizsgálati helyszín
Piedmont Fayette Hospital
Fayetteville, Georgia 30214, Egyesült ÁllamokMég nincs intézményhez kötve
- 18futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis19 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis3 vizsgálat
- Állapot
- Fut, nem toboroz15 vizsgálat
- Lezárult8 vizsgálat
- Toboroz2 vizsgálat
- Meghívásos bevonás1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- National Cancer Institute (NCI)12 vizsgálat
- NRG Oncology7 vizsgálat
- Cytokinetics4 vizsgálat
- Radiation Therapy Oncology Group2 vizsgálat
- SWOG Cancer Research Network2 vizsgálat
Futó vizsgálatok
Toboroz
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· 3. fázis· Cytokinetics· Forrás
Contact: Cytokinetics MD
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Adam W. Nowlan (principal investigator)
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Judy Langer
Fut, nem toboroz
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· 3. fázis· NRG Oncology· Forrás
Meghívásos bevonás
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506· 2/3. fázis· Cytokinetics· Forrás
Fut, nem toboroz
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NCT03180268· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· 3. fázis· Radiation Therapy Oncology Group· Forrás
Fut, nem toboroz
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00602641· 3. fázis· National Cancer Institute (NCI)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek